1
|
Sebti M, Schweitzer-Chaput A, Cisternino S, Hinterlang M, Ancedy D, Lam S, Auvity S, Cotteret C, Lortholary O, Schlatter J. Formulation and Stability of a 1% Clarithromycin-Based Topical Skin Cream: A New Option to Treat Buruli Ulcers? Pharmaceuticals (Basel) 2024; 17:691. [PMID: 38931358 PMCID: PMC11206874 DOI: 10.3390/ph17060691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2024] [Revised: 05/14/2024] [Accepted: 05/19/2024] [Indexed: 06/28/2024] Open
Abstract
There are more than 170 known species of non-tuberculous mycobacteria, and some are responsible for serious diseases in people infected with them. One of these is Buruli ulcers, a neglected tropical disease endemic in more than 33 countries and caused by Mycobacterium ulcerans, which infects skin tissue. Treatment consists of a long-term regimen combining the use of oral rifampin with another anti-tuberculosis drug (e.g., clarithromycin). Patients in these countries face difficulties in accessing and adhering to this therapy. This study investigates the feasibility of formulating stable, optimized clarithromycin as a topical cutaneous cream. The cream was formulated, and its stability was evaluated under different storage temperature conditions and using a stability indicator method. The results showed that the clarithromycin cream was stable for at least 60 days, even at extreme temperatures (40 °C). In conclusion, the data presented here demonstrate the stability of a new form of topical cutaneous clarithromycin, which may offer a new approach to the treatment of Buruli ulcers and clarithromycin-sensitive infections.
Collapse
Affiliation(s)
- Maria Sebti
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), 149 Rue de Sèvres, F-75015 Paris, France; (M.S.); (A.S.-C.); (M.H.); (D.A.); (S.L.); (S.A.); (C.C.); (J.S.)
| | - Arnaud Schweitzer-Chaput
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), 149 Rue de Sèvres, F-75015 Paris, France; (M.S.); (A.S.-C.); (M.H.); (D.A.); (S.L.); (S.A.); (C.C.); (J.S.)
| | - Salvatore Cisternino
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), 149 Rue de Sèvres, F-75015 Paris, France; (M.S.); (A.S.-C.); (M.H.); (D.A.); (S.L.); (S.A.); (C.C.); (J.S.)
- Faculté de Pharmacie, Université Paris Cité, Inserm UMRS 1144, 4, Avenue de l’Observatoire, F-75006 Paris, France
| | - Mélanie Hinterlang
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), 149 Rue de Sèvres, F-75015 Paris, France; (M.S.); (A.S.-C.); (M.H.); (D.A.); (S.L.); (S.A.); (C.C.); (J.S.)
| | - Dimitri Ancedy
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), 149 Rue de Sèvres, F-75015 Paris, France; (M.S.); (A.S.-C.); (M.H.); (D.A.); (S.L.); (S.A.); (C.C.); (J.S.)
| | - Sandrine Lam
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), 149 Rue de Sèvres, F-75015 Paris, France; (M.S.); (A.S.-C.); (M.H.); (D.A.); (S.L.); (S.A.); (C.C.); (J.S.)
| | - Sylvain Auvity
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), 149 Rue de Sèvres, F-75015 Paris, France; (M.S.); (A.S.-C.); (M.H.); (D.A.); (S.L.); (S.A.); (C.C.); (J.S.)
- Faculté de Pharmacie, Université Paris Cité, Inserm UMRS 1144, 4, Avenue de l’Observatoire, F-75006 Paris, France
| | - Camille Cotteret
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), 149 Rue de Sèvres, F-75015 Paris, France; (M.S.); (A.S.-C.); (M.H.); (D.A.); (S.L.); (S.A.); (C.C.); (J.S.)
| | - Olivier Lortholary
- Service des Maladies Infectieuses et Tropicales, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), F-75015 Paris, France;
- Institut Pasteur, Molecular Mycology Unit, National Reference Centre for Invasive Mycoses and Antifungals, CNRS UMR 2000, F-75015 Paris, France
- Institut Imagine, Hôpital Universitaire Necker—Enfants Malades, F-75105 Paris, France
| | - Joël Schlatter
- Service Pharmacie, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique des Hôpitaux de Paris (APHP), 149 Rue de Sèvres, F-75015 Paris, France; (M.S.); (A.S.-C.); (M.H.); (D.A.); (S.L.); (S.A.); (C.C.); (J.S.)
- Service Pharmacie, Hôpital Paul Doumer, Assistance Publique des Hôpitaux de Paris (APHP), 1 Rue de l’Hôpital, F-60140 Labruyère, France
| |
Collapse
|
2
|
Mohan S, Li Y, Chu K, De La Paz L, Sperger D, Shi B, Foti C, Rucker V, Lai C. Integrative Salt Selection and Formulation Optimization: Perspectives of Disproportionation and Microenvironmental pH Modulation. Mol Pharm 2024; 21:2590-2605. [PMID: 38656981 DOI: 10.1021/acs.molpharmaceut.4c00166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/26/2024]
Abstract
We report a novel utilization of a pH modifier as a disproportionation retardant in a tablet formulation. The drug molecule of interest has significant bioavailability challenges that require solubility enhancement. In addition to limited salt/cocrystal options, disproportionation of the potential salt(s) was identified as a substantial risk. Using a combination of Raman spectroscopy with chemometrics and quantitative X-ray diffraction in specially designed stress testing, we investigated the disproportionation phenomena. The learnings and insight drawn from crystallography drove the selection of the maleate form as the target API. Inspired by the fumarate form's unique stability and solubility characteristics, we used fumaric acid as the microenvironmental pH modulator. Proof-of-concept experiments with high-risk (HCl) and moderate-risk (maleate) scenarios confirmed the synergistic advantage of fumaric acid, which interacts with the freebase released by disproportionation to form a more soluble species. The resultant hemifumarate helps maintain the solubility at an elevated level. This work demonstrates an innovative technique to mediate the solubility drop during the "parachute" phase of drug absorption using compendial excipients, and this approach can potentially serve as an effective risk-mitigating strategy for salt disproportionation.
Collapse
Affiliation(s)
- Shikhar Mohan
- Gilead Sciences, Inc., Foster City, California 94404, United States
| | - Yi Li
- Gilead Sciences, Inc., Foster City, California 94404, United States
| | - Kevin Chu
- Velexi Corporation, Burlingame, California 94010, United States
| | | | - Diana Sperger
- Gilead Sciences, Inc., Foster City, California 94404, United States
| | - Bing Shi
- Gilead Sciences, Inc., Foster City, California 94404, United States
| | - Chris Foti
- Gilead Sciences, Inc., Foster City, California 94404, United States
| | - Victor Rucker
- Gilead Sciences, Inc., Foster City, California 94404, United States
| | - Chiajen Lai
- Gilead Sciences, Inc., Foster City, California 94404, United States
| |
Collapse
|
3
|
Mardikasari SA, Katona G, Sipos B, Csóka I. Essential considerations towards development of effective nasal antibiotic formulation: features, strategies, and future directions. Expert Opin Drug Deliv 2024; 21:611-625. [PMID: 38588551 DOI: 10.1080/17425247.2024.2341184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 04/05/2024] [Indexed: 04/10/2024]
Abstract
INTRODUCTION Intranasal antibiotic products are gaining popularity as a promising method of administering antibiotics, which provide numerous benefits, e.g. enhancing drug bioavailability, reducing adverse effects, and potentially minimizing resistance threats. However, some issues related to the antibiotic substances and nasal route challenges must be addressed to prepare effective formulations. AREAS COVERED This review focuses on the valuable points of nasal delivery as an alternative route for administering antibiotics, coupled with the challenges in the nasal cavity that might affect the formulations. Moreover, this review also highlights the application of nasal delivery to introduce antibiotics for local therapy, brain targeting, and systemic effects that have been conducted. In addition, this viewpoint provides strategies to maintain antibiotic stability and several crucial aspects to be considered for enabling effective nasal formulation. EXPERT OPINION In-depth knowledge and understanding regarding various key considerations with respect to the antibiotic substances and nasal route delivery requirement in preparing effective nasal antibiotic formulation would greatly improve the development of nasally administered antibiotic products, enabling better therapeutic outcomes of antibiotic treatment and establishing appropriate use of antibiotics, which in turn might reduce the chance of antibiotic resistance and enhance patient comfort.
Collapse
Affiliation(s)
- Sandra Aulia Mardikasari
- Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Szeged, Hungary
- Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia
| | - Gábor Katona
- Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Szeged, Hungary
| | - Bence Sipos
- Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Szeged, Hungary
| | - Ildikó Csóka
- Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Szeged, Hungary
| |
Collapse
|
4
|
Pu YE, Menger R, Tong Z, Gaebele T. Development of an enhanced formulation to minimize pharmacokinetic variabilities of a weakly basic drug compound. Pharm Dev Technol 2022; 27:406-413. [PMID: 35502986 DOI: 10.1080/10837450.2022.2070206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Formulating poorly water soluble, weakly basic drugs with consistent exposure is often a challenge due to pH dependent solubility. When the oral formulation is exposed to different pH ranges in the gastrointestinal (GI) tract, drug precipitation or incomplete dissolution may occur resulting in decreased drug absorption and higher intra-and inter-patient pharmacokinetic variabilities.In the present study, a series of enhanced formulations containing organic acids and/or surfactants were developed and compared with conventional formulations with respect to their in vitro dissolution performance. The formulation containing 5% citric acid and 1% sodium lauryl sulfate (SLS) showed much less variations in dissolution performance at different pH conditions than a conventional formulation. The combination of citric acid and SLS demonstrated a synergistic effect as compared to use of citric acid alone or in combination with PEG4000 as a precipitation inhibitor.When compared with a conventional formulation and a spray-dried amorphous solid dispersion (ASD) formulation in a dog pharmacokinetics study, the enhanced formulation demonstrated the least AUC and Cmax variability between the two gastric pH-controlled groups. In conclusion, an enhanced formulation using a combination of organic acid and surfactant is recommended for weakly basic drug compounds to minimize drug pharmacokinetic variabilities in clinical studies.
Collapse
Affiliation(s)
- Yu Elaine Pu
- Oral Product Development, Global Pharmaceutical Sciences, Bristol-Myers Squibb
| | - Robert Menger
- Analytical Chemistry, Chemical Process Development, Bristol-Myers Squibb
| | - Zeen Tong
- Drug Metabolism and Pharmacokinetics, Nonclinical Disposition Assessment, Bristol-Myers Squibb
| | - Tracy Gaebele
- Material Science and Engineering, Global Pharmaceutical Sciences, Bristol-Myers Squibb
| |
Collapse
|
5
|
Zakowiecki D, Hess T, Cal K, Mikolaszek B, Garbacz G, Haznar-Garbacz D. Directly compressible formulation of immediate release rosuvastatin calcium tablets stabilized with tribasic calcium phosphate. Pharm Dev Technol 2022; 27:425-434. [DOI: 10.1080/10837450.2022.2073370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | - Tobias Hess
- Chemische Fabrik Budenheim KG, Budenheim, Germany
| | - Krzysztof Cal
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland
| | - Barbara Mikolaszek
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical University of Gdansk, Gdansk, Poland
| | - Grzegorz Garbacz
- Physiolution Polska sp. z o.o, Wroclaw, Poland
- Physiolution GmbH, Greifswald, Germany
| | - Dorota Haznar-Garbacz
- Department of Drug Form Technology, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland
| |
Collapse
|
6
|
Abstract
Telmisartan (TEL) is an antihypertensive BCS class II drug with low solubility at physiological pH. However, the solubility of TEL increases with the presence of an alkalizer. Electrospinning is one of the most recent techniques for the solubility enhancement studies. In this study, an electrospun orally disintegrating film (ODF) formulation of TEL was developed with L-arginine and polyvinylpyrrolidone K90 (PVP), and its characterization studies were performed. Preformulation studies were performed to investigate possible incompatibilities in the components of formulation with differential scanning calorimetry (DSC) and Fourier transform infrared spectrometer (FT-IR) analyses. ODFs were characterized in terms of drug content and uniformity, mechanical properties, fiber shape and diameter and in vitro dissolution profile. Smooth nanofibers without any beads were obtained. The dissolution rate of the TEL significantly increased. The chosen formulation had acceptable mechanical properties with much faster dissolution compared to the commercially available product. Developed ODF and marketed product were compared with a dissolution study in phosphate-buffered solution (pH 7.4). ODF and marketed product both reached 100% release in the 45th minute, and ODF results showed that ODF had much faster release than marketed product. In this study, TEL ODF formulation was successfully produced and characterized.
Collapse
Affiliation(s)
- Mehmet Birer
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Gazi University, Ankara, Turkey
| | - Füsun Acartürk
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Gazi University, Ankara, Turkey
| |
Collapse
|
7
|
Liu H, Wang S, Shi H, Zhang R, Qu K, Hu Y, Qu X, Gan C, Chen J, Shi X, Zhang M, Zeng W. Gastric floating tablet improves the bioavailability and reduces the hypokalemia effect of gossypol in vivo. Saudi Pharm J 2021; 29:305-314. [PMID: 33994825 PMCID: PMC8093546 DOI: 10.1016/j.jsps.2021.03.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2020] [Accepted: 03/01/2021] [Indexed: 11/16/2022] Open
Abstract
Gossypol (Gos) is a natural polyphenolic compound that has shown a number of valuable biological properties such as antifertility, antioxidation, and antitumor activities. However, the clinical application of Gos has been hindered by its notable adverse effects such as hypokalemia, hemolytic anemia, and so on. Using sustained-release dosage form provides a hopeful solution to this problem. In this study, a gastric floating tablet for sustained-release of Gos (Gos-GFT) was developed using polyvinylpyrrolidone, hydroxypropyl methyl cellulose, ethyl cellulose, lactose, sodium bicarbonate, and magnesium stearate. Gos-GFT had an average weight of around 200 mg with a drug content percentage of around 13.66%. The physicochemical properties of Gos-GFT satisfied the pharmacopoeial requirements for tablets. Gos-GFT was able to float in an acidic medium and had a sustained drug release for over 12 h. In vivo studies showed that the relative bioavailability of Gos-GFT, as compared with Gos powders, was larger than that of a non-gastric floating tablet which was a dosage form used for comparison with Gos-GFT. Furthermore, compared with the Gos powders and the non-gastric floating Gos tablets, Gos-GFT could prolong the in vivo action time of Gos, and significantly relieve hypokalemia which is a major adverse effect of Gos. These properties made Gos-GFT a promising Gos preparation that warrants further investigation for more extensive clinical applications of this natural compound.
Collapse
Affiliation(s)
- Hao Liu
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Sijiao Wang
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Houyin Shi
- Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Ruirui Zhang
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Kunyan Qu
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Yue Hu
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Xingyu Qu
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Chenyun Gan
- School of Clinical Medicine, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Jingjing Chen
- School of Clinical Medicine, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Xinyu Shi
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Mengwu Zhang
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Weiling Zeng
- Department of Scientific Research, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| |
Collapse
|
8
|
Liu H, Gan C, Shi H, Qu K, Jing L, Lu M, Su B, Yu H, Yuan H, Chen J, Zhang R, Zeng W. Gastric floating pill enhances the bioavailability and drug efficacy of dihydromyricetin in vivo. J Drug Deliv Sci Technol 2021. [DOI: 10.1016/j.jddst.2020.102279] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
9
|
Ambay TM, Schick P, Grimm M, Sager M, Schneider F, Koziolek M, Siegmund W, Schindele F, Haas R, Weitschies W. Design and Optimization of a Novel Strategy for the Local Treatment of Helicobacter pylori Infections. J Pharm Sci 2020; 110:1302-1309. [PMID: 33253724 DOI: 10.1016/j.xphs.2020.11.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Revised: 11/03/2020] [Accepted: 11/20/2020] [Indexed: 12/01/2022]
Abstract
Infections with Helicobacter pylori are a global challenge. Currently, H. pylori infections are treated systemically, but the eradication rates of the different therapy regimens are declining due to the growing number of bacterial strains resistant to major antibiotics. Here, we present a strategy for the local eradication of H. pylori by the use of Penicillin G sodium (PGS). In vitro experiments revealed that PGS shows high antibiotic activity against resistant strains of Helicobacter pylori with a minimum inhibitory concentration (MIC) of 0.125 μg/ml. In order to provide luminal concentrations above the MIC for longer periods of time, an extended release tablet was developed. Alkalizers were included to prevent acidic degradation of PGS within the tablet matrix. Out of the tested alkalizers MgO, l-Lysine, NaHCO3, and Na2CO3 NaHCO3 provided the strongest rise in pH inside the hydrated matrix when tested in simulated gastric fluid. Better PGS stability can mainly reasoned from that, addition of MgO resulted in high pH values within the matrix, causing basic degradation of PGS. This work is a first step towards the use of extended release tablets containing PGS for the local treatment of H. pylori as a safe and cost-effective alternative to common systemic treatment regimens.
Collapse
Affiliation(s)
- Taddese Mekonnen Ambay
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany
| | - Philipp Schick
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany
| | - Michael Grimm
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany
| | - Maximilian Sager
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany
| | - Felix Schneider
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany
| | - Mirko Koziolek
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany
| | - Werner Siegmund
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport, University Medicine, Greifswald, Germany
| | - Franziska Schindele
- Chair of Medical Microbiology and Hospital Epidemiology, Max von Pettenkofer Institute, Faculty of Medicine, LMU Munich, Germany
| | - Rainer Haas
- Chair of Medical Microbiology and Hospital Epidemiology, Max von Pettenkofer Institute, Faculty of Medicine, LMU Munich, Germany
| | - Werner Weitschies
- Department of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport, University of Greifswald, Greifswald, Germany.
| |
Collapse
|
10
|
Pardhi VP, Flora S. Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder. Biopharm Drug Dispos 2020; 41:334-351. [PMID: 33080060 DOI: 10.1002/bdd.2252] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 09/08/2020] [Accepted: 10/07/2020] [Indexed: 12/30/2022]
Abstract
Crystalline solid dispersion of lurasidone hydrochloride (LH) was made with various polar and non-polar small molecules to overcome the poor aqueous solubility issue. LH-Glutathione (GSH) solid dispersion in 1:1 ratio was prepared by co-grinding method and characterized by using differential scanning calorimetry (DSC), powder X-ray diffraction, Fourier transform infrared spectroscopy (FTIR) and Raman spectroscopy. GSH acts as antioxidant and reported for anti-schizophrenic activity may provide synergistic action with LH or reduce the side effects. LH in LH-GSH solid dispersion (SD) has shown improvement in solubility by 7.9 folds than plain drug which translated in terms of improved dissolution rate by two-folds. The in vitro dissolution results showed maximum dissolution rate with LH-GSH SD (97.85 ± 2.40%) compared to plain drug (50.5 ± 3.02%) at 15 min (t15 min, %) and thus, satisfying criteria of immediate release dosage form. DSC and FTIR data confirmed the stability of LH-GSH SD for 3 months at accelerated stability condition (40 ± 2°C and 75 ± 5% RH). The prepared LH-GSH SD can be used as a tool to target dual problems that is, enhanced physicochemical properties along with possible management of disorder which could be due to synergism with co-administered GSH. This approach is thought to be efficiently providing the relief to the psychological patients.
Collapse
Affiliation(s)
- Vishwas P Pardhi
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Raebareli, Lucknow, Uttar Pradesh, India
| | - Swaran Flora
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Raebareli, Lucknow, Uttar Pradesh, India
| |
Collapse
|
11
|
Maderuelo C, Lanao JM, Zarzuelo A. Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability. Eur J Pharm Sci 2019; 138:105019. [DOI: 10.1016/j.ejps.2019.105019] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 07/10/2019] [Accepted: 07/28/2019] [Indexed: 02/07/2023]
|
12
|
Panizzon GP, Giacomini Bueno F, Ueda-Nakamura T, Nakamura CV, Dias Filho BP. Manufacturing Different Types of Solid Dispersions of BCS Class IV Polyphenol (Daidzein) by Spray Drying: Formulation and Bioavailability. Pharmaceutics 2019; 11:E492. [PMID: 31557831 PMCID: PMC6835336 DOI: 10.3390/pharmaceutics11100492] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2019] [Revised: 09/13/2019] [Accepted: 09/16/2019] [Indexed: 12/22/2022] Open
Abstract
Daidzein (DZ) is a polyphenolic compound belonging to Biopharmaceutical Classification System class IV, which shows that it may have limited therapeutic effects due to its low solubility and poor bioavailability. This study aimed to obtain high-purity DZ and prepare and characterize different types of solid dispersions (SDs) in order to enhance aqueous solubility and bioavailability. Excipients were investigated in order to manufacture different types of solid dispersions (SDs). Second-generation solid dispersions (SG), third-generation solid dispersions (TG), and second- and third-generation pH-modulated solid dispersions (SD and TG pHM-SD) were produced via spray drying. The SDs were characterized and tested for in vitro DZ release and oral bioavailability. SDs have shown increased aqueous solubility and in vitro release rate. Solid-state characterization showed that DZ was in an amorphous state in most of the formulations. The enhanced aqueous solubility of TG-pHM SD was reflected by an increase in oral bioavailability, which significantly increased the maximum plasma concentration approximately 20-fold and decreased the time to reach the maximum plasma concentration. The production of pHM SDs that contain DZ via spray drying is a simple and effective approach for oral drug delivery, which has the potential to greatly reduce the dose and enhance therapeutics effects.
Collapse
Affiliation(s)
- Gean Pier Panizzon
- Post-graduate Program in Pharmaceutical Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Maringá 87020-900, Paraná, Brazil.
| | - Fernanda Giacomini Bueno
- Medical and Pharmaceutical Sciences Center, Western Paraná State University, Cascavel 85819-110, Paraná, Brazil.
| | - Tânia Ueda-Nakamura
- Post-graduate Program in Pharmaceutical Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Maringá 87020-900, Paraná, Brazil.
| | - Celso Vataru Nakamura
- Post-graduate Program in Pharmaceutical Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Maringá 87020-900, Paraná, Brazil.
| | - Benedito Prado Dias Filho
- Post-graduate Program in Pharmaceutical Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Maringá 87020-900, Paraná, Brazil.
| |
Collapse
|
13
|
Liu H, Zhao W, Hu Q, Zhao L, Wei Y, Pi C, Yang Y, Yang X, Yuan H, Zhang Y, Qu K, Shi X, Huang Y, Shi H. Gastric floating sustained-release tablet for dihydromyricetin: Development, characterization, and pharmacokinetics study. Saudi Pharm J 2019; 27:1000-1008. [PMID: 31997907 PMCID: PMC6978620 DOI: 10.1016/j.jsps.2019.08.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 08/07/2019] [Indexed: 02/06/2023] Open
Abstract
Dihydromyricetin (DHM) is a natural dihydroflavonol compound with quite a number of important pharmacological properties. However, its low solubility in water and poor stability in aqueous environment, have compromised drug efficacy of DHM, thus hindering its clinical use. The present study was to develop DHM-loaded gastric floating sustained-release tablet (DHM-GFT) to improve the bioavailability of DHM. DHM-GFT was prepared via powder direct compression. The formulation of tablet was optimized in terms of the floating ability and drug release rate. The optimized DHM-GFT exhibited short floating lag time of less than 10 s and long floating duration of over 12 h in acidic medium. It had a 12-hour sustained release of DHM, which proved its potential to develop as a twice-a-day dosing preparation. The physicochemical properties of DHM-GFT well satisfied the pharmacopoeial requirements. In addition, the results from pharmacokinetic studies demonstrated that, DHM-GFT could considerably prolong the in vivo residence time of drug and improve the bioavailability via good gastric floating ability and sustained drug release when compared to DHM powder. Therefore, DHM-GFT is promising to promote the application of DHM and merits studies for further development.
Collapse
Affiliation(s)
- Hao Liu
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Wenmei Zhao
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Qi Hu
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Ling Zhao
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Yumeng Wei
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Chao Pi
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Yuhan Yang
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Xuerong Yang
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Hang Yuan
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Yuhan Zhang
- School of Clinical Medicine, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Kunyan Qu
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Xinyu Shi
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Yao Huang
- School of Pharmacy, Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| | - Houyin Shi
- Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou City, Sichuan, People's Republic of China
| |
Collapse
|
14
|
Park C, Meghani NM, Shin Y, Oh E, Park JB, Cui JH, Cao QR, Tran TTD, Tran PHL, Lee BJ. Investigation of Crystallization and Salt Formation of Poorly Water-Soluble Telmisartan for Enhanced Solubility. Pharmaceutics 2019; 11:pharmaceutics11030102. [PMID: 30823389 PMCID: PMC6470926 DOI: 10.3390/pharmaceutics11030102] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2019] [Revised: 02/17/2019] [Accepted: 02/21/2019] [Indexed: 01/13/2023] Open
Abstract
The crystal changes and salt formation of poorly water-soluble telmisartan (TEL) in various solvents were investigated for enhanced solubility, stability and crystallinity. Polymorphic behaviors of TEL were characterized by dispersing in distilled water, acetone, acetonitrile, DMSO, or ethanol using Method I: without heat and then dried under vacuum at room temperature; and Method II: with heat below boiling temperature, cooled at 5 °C, and then dried under vacuum at 40 °C. For salt formation (Method III), the following four powdered mixtures were prepared by dispersing in solution of hydrochloric acid (HCl) (pH 1.2), TEL/HCl; in simulated gastric fluid (pH 1.2 buffer), TEL/simulated gastric fluid (SGF); in intestinal fluid (pH 6.8 buffer), TEL/simulated intestinal fluid (SIF); or in NaOH (pH 6.8), TEL/NaOH, respectively, and then dried under a vacuum at room temperature. The structures of powdered mixtures were then studied using a field emission scanning electron microscope (FESEM), differential scanning calorimetry (DSC), powder X-ray diffraction (PXRD), FTIR, ¹H nuclear magnetic resonance (¹H-NMR), and LC⁻MS. The solubility of TEL in powdered forms was performed in pH 6.8, pH 1.2, and distilled water. No polymorphic behaviors of TEL were observed in various solvents as characterized by FESEM, DSC, PXRD, and FTIR. However, the structural changes of powdered mixtures obtained from Method III were observed due to the formation of salt form. Moreover, the solubility of salt form (TEL/HCl) was highly increased as compared with pure TEL. There were no significant changes of TEL/HCl compared with TEL in the content assay, PXRD, DSC, and FTIR during stressed storage conditions at 40 °C/75% relative humidity (RH) for 4 weeks under the closed package condition. Therefore, the present study suggests the new approach for the enhanced stability and solubility of a poorly water-soluble drug via salt form.
Collapse
Affiliation(s)
- Chulhun Park
- College of Pharmacy, Ajou University, Suwon 16499, Korea.
| | | | - Yongkwan Shin
- College of Pharmacy, Ajou University, Suwon 16499, Korea.
| | - Euichaul Oh
- College of Pharmacy, The Catholic University of Korea, Bucheon 14662, Korea.
| | - Jun-Bom Park
- College of Pharmacy, Sahmyook University, Seoul 01795, Korea.
| | - Jing-Hao Cui
- College of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.
| | - Qing-Ri Cao
- College of Pharmaceutical Sciences, Soochow University, Suzhou 215006, China.
| | - Thao Truong-Dinh Tran
- Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, Vietnam.
- Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City, Vietnam.
| | | | - Beom-Jin Lee
- College of Pharmacy, Ajou University, Suwon 16499, Korea.
| |
Collapse
|
15
|
Formulation and biopharmaceutical evaluation of supersaturatable self-nanoemulsifying drug delivery systems containing silymarin. Int J Pharm 2019; 555:63-76. [DOI: 10.1016/j.ijpharm.2018.11.036] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Revised: 11/05/2018] [Accepted: 11/14/2018] [Indexed: 12/23/2022]
|
16
|
Tung NT, Tran CS, Nguyen TL, Hoang T, Trinh TD, Nguyen TN. Formulation and biopharmaceutical evaluation of bitter taste masking microparticles containing azithromycin loaded in dispersible tablets. Eur J Pharm Biopharm 2018; 126:187-200. [DOI: 10.1016/j.ejpb.2017.03.017] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 03/23/2017] [Accepted: 03/24/2017] [Indexed: 01/27/2023]
|
17
|
Liu R, Li P, Xiao J, Yin Y, Sun Z, Bi K, Li Q. A fast, sensitive, and high throughput method for the determination of esomeprazole in dog plasma by UHPLC–MS/MS: Application to formulation development of the compound preparation of esomeprazole. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1068-1069:352-357. [DOI: 10.1016/j.jchromb.2017.11.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Revised: 10/07/2017] [Accepted: 11/02/2017] [Indexed: 12/12/2022]
|
18
|
Van Nguyen H, Baek N, Lee BJ. Enhanced gastric stability of esomeprazole by molecular interaction and modulation of microenvironmental pH with alkalizers in solid dispersion. Int J Pharm 2017; 523:189-202. [DOI: 10.1016/j.ijpharm.2017.03.047] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 03/14/2017] [Accepted: 03/20/2017] [Indexed: 12/27/2022]
|
19
|
Kang WH, Nguyen HV, Park C, Choi YW, Lee BJ. Modulation of microenvironmental pH for dual release and reduced in vivo gastrointestinal bleeding of aceclofenac using hydroxypropyl methylcellulose-based bilayered matrix tablet. Eur J Pharm Sci 2017; 102:85-93. [DOI: 10.1016/j.ejps.2017.02.039] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2016] [Revised: 01/16/2017] [Accepted: 02/27/2017] [Indexed: 11/24/2022]
|
20
|
Cyphert EL, Wallat JD, Pokorski JK, von Recum HA. Erythromycin Modification That Improves Its Acidic Stability while Optimizing It for Local Drug Delivery. Antibiotics (Basel) 2017; 6:antibiotics6020011. [PMID: 28441360 PMCID: PMC5485444 DOI: 10.3390/antibiotics6020011] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Revised: 03/02/2017] [Accepted: 04/19/2017] [Indexed: 11/24/2022] Open
Abstract
The antibiotic erythromycin has limited efficacy and bioavailability due to its instability and conversion under acidic conditions via an intramolecular dehydration reaction. To improve the stability of erythromycin, several analogs have been developed—such as azithromycin and clarithromycin—which decrease the rate of intramolecular dehydration. We set out to build upon this prior work by developing a conjugate of erythromycin with improved pH stability, bioavailability, and preferential release from a drug delivery system directly at the low pH of an infection site. To develop this new drug conjugate, adamantane-1-carbohydrazide was covalently attached to erythromycin via a pH-degradable hydrazone bond. Since Staphylococcus aureus infection sites are slightly acidic, the hydrazone bond will undergo hydrolysis liberating erythromycin directly at the infection site. The adamantane group provides interaction with the drug delivery system. This local delivery strategy has the potential of reducing off-target and systemic side-effects. This work demonstrates the synthesis of a pH-cleavable, erythromycin conjugate that retains the inherent antimicrobial activity of erythromycin, has an increased hydrophobicity, and improved stability in acidic conditions; thereby enhancing erythromycin’s bioavailability while simultaneously reducing its toxicity.
Collapse
Affiliation(s)
- Erika L Cyphert
- Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
| | - Jaqueline D Wallat
- Department of Macromolecular Science and Engineering, Case Western Reserve University, 2100 Adelbert Road, Cleveland, OH 44106, USA.
| | - Jonathan K Pokorski
- Department of Macromolecular Science and Engineering, Case Western Reserve University, 2100 Adelbert Road, Cleveland, OH 44106, USA.
| | - Horst A von Recum
- Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
| |
Collapse
|
21
|
New blends of hydroxypropylmethylcellulose and Gelucire 44/14: physical property and controlled release of drugs with different solubility. JOURNAL OF PHARMACEUTICAL INVESTIGATION 2017. [DOI: 10.1007/s40005-017-0322-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Kim DW, Park JB. Development and pharmaceutical approach for sustained-released metformin succinate tablets. J Drug Deliv Sci Technol 2015. [DOI: 10.1016/j.jddst.2015.09.019] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|